The National Institute for Health and Care Excellence (NICE) recently updated its guideline on pharmacological treatments for attention deficit hyperactivity disorder (ADHD).The guideline builds on evidence reviews with serious methodological limitations concerning multiplicity, imprecision, selective reporting, and short-term data.Strong clinical practice recommendations for methylphenidate and lisdexamfetamine are informed by GRADE-evaluated, low-quality studies and subjective value judgements.This article critically discusses the updated NICE guideline on pharmacological treatments for ADHD and proposes concrete solutions to address the issues at hand.
No takes yet. Share an insight, caveat, or question.
Faltinsen et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: